innovation medicines initiative

��ֳ� and Ailux Biologics Join Forces to Transform Biologics Research

Andrea_Puletto — Thu, 09 Jan 2025 13:38:36 +0000

��ֳ� and Ailux Biologics Join Forces to Transform Biologics Research

Dan Lightwood, Antibody Discovery and Optimisation

Andrea_Puletto Thu 09/01/2025 - 14:38

At ��ֳ�, our commitment to innovation is driven by one clear objective – to transform the lives of people living with severe diseases. Each partnership we pursue is carefully chosen to not only align with this mission but to amplify it. That's why we are thrilled to announce a groundbreaking collaboration with Ailux Biologics, a division of XtalPi, to propel biologics research into new territory.

This strategic partnership highlights ��ֳ�'s ongoing dedication to addressing unmet medical needs, harnessing cutting-edge technologies, and shaping a future where healthcare solutions are developed faster, smarter, and more effectively.

A Powerful Alliance for Scientific Innovation

Through our partnership with Ailux Biologics, we’ve licensed XtalFold™, an AI-powered biologics platform designed to provide rapid and accurate insights into antibody and antigen structures. By integrating this sophisticated technology into our biologics discovery and optimization workflows, we’re equipping our teams with enhanced capabilities to engineer high-quality therapeutic candidates more efficiently. We believe XtalFold™ has the potential to enhance ��ֳ�’s ability to rapidly and efficiently discover therapeutic antibody candidates and ultimately deliver new medicines to patients.

XtalFold™ sets itself apart by leveraging sequence information alone to predict biomolecular interactions, including the crucial antibody-antigen interface. This streamlined, sequence-driven approach offers exceptional precision, even in complex regions that were challenging to model in the past.

Addressing Unmet Needs Through Technology

With around 70% of immune and central nervous system diseases still classified as having unmet medical needs, accelerating the discovery of effective therapies is critical. XtalFold will allow us to leverage structural insights into the entire antibody discovery and optimisation workflow; allowing us to be more efficient in how we select and engineer antibodies with suitable drug-like properties.

Coupled with ��ֳ�’s robust in-house antibody discovery platforms, this collaboration establishes a dynamic synergy between human expertise and computational power. It’s a blend of innovation and experience that further strengthens our ability to bring meaningful solutions to patients around the world.

Anticipating the Path Ahead

This isn’t just a collaboration to benefit the present; it’s a strategic move that looks towards the future of biologics development. ��ֳ� and Ailux Biologics will continue to explore the full potential of AI in discovery processes, aiming to deliver milestones that redefine therapeutic solutions. By adopting state-of-the-art platforms, we expect to not only accelerate drug discovery but foster an environment where innovation thrives.

We’re proud of what this partnership signals not just for ��ֳ� but for patients around the globe. Together with Ailux Biologics, we will continue to challenge the boundaries of science, and work to open doors to treatments that were once unimaginable. This is only the beginning, and as we move forward, our vision remains unwavering – transforming lives, one discovery at a time.

innovation

Comment:

Posted by Cecilia, 30 January 2025

Amazing news

178 Likes

Healthcare Innovation: ��ֳ� and KU Leuven’s Collaborative Approach

Andrea_Puletto — Wed, 18 Sep 2024 09:12:23 +0000

Healthcare Innovation: ��ֳ� and KU Leuven’s Collaborative Approach

By Julie Tordo, Preclinical Gene Therapy

Andrea_Puletto Wed 18/09/2024 - 11:12

At ��ֳ�, we recognize that we cannot solve the world’s healthcare challenges alone, but that breakthroughs will result from the use of new technologies as well as open collaboration and partnerships. In fact, we believe that collaboration serves as a catalyst for advancement in science discovery. That is why we work hard to find great partners, because we know that the more, we collaborate, the more we can innovate.

The power of collaborations in fostering innovation cannot be understated. It’s about enabling diverse expertise to converge and tackle complex challenges from multiple angles. When researchers, academics, clinicians, and technology experts join forces they can work with agility, share insights, and leverage unique resources and experiences, all of which can expedite the journey from concept to innovation.

While vital for innovation, collaborations often come with their own set of challenges. Differences in culture, priorities and ways of working can create friction, leading to misunderstandings or misaligned expectations. Building trust is essential to navigate these complexities. It requires open communication and a willingness to empathize with one another’s perspectives. By fostering an environment where both parties feel valued and heard, we can collaboratively address these hurdles, paving the way for more successful partnerships.

I believe that trust is something we have established with KU Leuven, a world leading university and partner to ��ֳ�. At the heart of this partnership is a shared commitment to transforming cutting-edge scientific discoveries into therapeutic solutions. The collaboration brings together complementary skills and expertise provided by each partner, combining the theoretical, creative and experimental expertise of academia with the strategic and operational capabilities of pharma. The strength of the ��ֳ�-KU Leuven partnership is built on a foundation of trust and shared objectives, essential for nurturing an environment where innovative ideas can thrive. Our collaboration with KU Leuven, in the field of gene therapy, exemplifies how partnerships can drive scientific thinking. to accelerate progress towards new innovations.

Find out more about our passion for innovation here.

innovation

innovation innovation medicines initiative discovery

130 Likes

Embracing patient-centered research: the transformative power of partnership

Andrea_Puletto — Fri, 28 Jun 2024 08:15:13 +0000

Embracing patient-centered research: the transformative power of partnership

Donatello Crocetta

Andrea_Puletto Fri 28/06/2024 - 10:15

As we gather at the 10th Congress of the European Academy of Neurology (EAN) in Helsinki, we look forward to engaging in discussions about the latest scientific progress and clinical advances in patient management. However, amidst the ever-evolving healthcare landscape, one concept stands out as a guiding principle for transformative progress: patient-centered research. By placing patients at the forefront of scientific inquiry, we can drive innovation, improve patient outcomes, and shape human-centric science.

Understanding the patient perspective

Patient-centered research begins by recognizing that patients are not passive recipients of care but active partners in the research process. Their insights and experiences provide invaluable guidance for scientists and clinicians. By listening to patients, we gain a deeper understanding of the impact of diseases on their lives, uncover unmet needs, and identify areas for improvement. This empathetic approach fosters a collaborative environment where patients and researchers work hand in hand to drive innovation.

At ��ֳ�, we firmly believe that this form of partnership is more transformative than any other. By building trusted relationships with patients, we gain insights into the personal impact of their conditions that cannot be obtained from trial data or the test tube alone. This partnership aligns the medical and clinical perspectives of professionals with the holistic perspective of patients' life experiences. By working together, we can amplify the success of new discoveries and create breakthrough innovations.

The power of partnership

Partnership with patients is a valued relationship that requires investment and long-term commitment. It enables us to align efforts, maximize results, and address challenges from different perspectives. By prioritizing the individual needs, preferences, and experiences of patients, we can drive personalized healthcare. For example, in our clinical trials, we strive to make participation as easy as possible, minimizing disruption to participants' day-to-day lives.

By combining patient-centered design with innovative technologies, we increase flexibility and optionality. So, for example, our understanding of myasthenia gravis (MG) has been enhanced by the MG Symptoms PRO scales, a tool co-developed by ��ֳ� with over 90 adults living with MG and MG clinicians that provides a quantifiable means of assessing MG symptoms, aligning with patients' lived experiences and paving the way for the development of enhanced management strategies.

Enhancing research through patient insights

By actively listening to patients and incorporating their insights, we can enhance the quality and relevance of our research. Patient-reported outcomes, such as fatigue and symptom improvement, provide valuable insights into the effectiveness of therapies and help us address the holistic well-being of patients. This data-driven approach ensures that our research is grounded in objective evidence and tailored to individual needs.

��ֳ� is committed to patient-centered research, as evidenced by our focus on understanding the symptom burden and impact of rare diseases like MG. At this year's EAN congress, we are showcasing data that highlight patient-reported outcomes, such as fatigue and symptom control.

Now that we’ve moved away from seeing patients as just patients, let’s continue to prioritize the insights from people’s lived experiences to drive transformative advancements in healthcare. Let us invest in building trusted relationships with patients, listening to their perspectives, and collaborating to drive innovation. It is fitting that EAN occurs during Myasthenia Gravis Awareness Month, which highlights the urgency to take action to address the high disease and treatment burden on people living with MG and the importance of listening to their individual needs to help improve treatment outcomes. Together, we can create a future where patient-centered research is not just a guiding principle, but a fundamental approach that shapes science and improves the lives of patients worldwide.

To learn more about our culture and how innovation drives everything we do, visit Innovation is | ��ֳ�.

about ucb

innovation innovation medicines initiative Rare Disease

228 Likes

��ֳ�'s Commitment to Innovation in Drug Development

Andrea_Puletto — Wed, 29 May 2024 09:28:09 +0000

��ֳ�'s Commitment to Innovation in Drug Development

Fleming Scott, Global Business & R&D Comms

Andrea_Puletto Wed 29/05/2024 - 11:28

Today marked the start of the Liver Ring Trial, the first cross-pharma validation trial to validate the reproducibility and accuracy of a human liver Micro-Physiological System (MPS) in predicting drug-induced liver injury (DILI) and hepatic clearance. As one of the initiators of the Liver Ring Trial, we at ��ֳ� are thrilled to be a part of this pioneering initiative.

The trial leverages TissUse's groundbreaking organ-on-chip technology and esqLABS' advanced computational modelling to enhance drug safety assessment. The consortium aims to evaluate the robustness of MPS data across different laboratories and to provide the confidence to use MPS data to support decision making and, ultimately, regulatory submission. If successful, the effort should change the paradigm in non-clinical drug assessment from current simplified systems to complex in vitro models with improved translation to human studies.

The Liver Ring Trial will be conducted by six pharma companies across Europe (��ֳ�, Sanofi, AstraZeneca, Boehringer Ingelheim, Servier, Orion Pharma), TissUse (MPS platform provider), and ESQLabs (expert for AI/ML-based modelling and simulation solutions).

Guided by the support from the European Medicines Agency (EMA) and the European Center for the Validation of Alternative Methods (ECVAM), the Liver Ring Trial pioneers the use of MPS as the next level in preclinical drug assessment.

��ֳ� scientists, Benoit Cox (senior scientist, in vitro ADME), Andre Rodrigues (post-doc scientist, in vitro toxicology) and Reiner Class (Associate Director, in vitro ADME) have generated the scientific and strategic basis for the trial and will lead the consortium.

You can read the full press release here.

innovation

innovation medicines initiative Innovation Our Science

292 Likes

innovation medicines initiative

��ֳ� and Ailux Biologics Join Forces to Transform Biologics Research

A Powerful Alliance for Scientific Innovation

Addressing Unmet Needs Through Technology

Anticipating the Path Ahead

Leave a Comment

Healthcare Innovation: ��ֳ� and KU Leuven’s Collaborative Approach

Leave a Comment

Embracing patient-centered research: the transformative power of partnership

Understanding the patient perspective

The power of partnership

Enhancing research through patient insights

Leave a Comment

��ֳ�'s Commitment to Innovation in Drug Development

Leave a Comment

innovation medicines initiative

������ֳ� and Ailux Biologics Join Forces to Transform Biologics Research

A Powerful Alliance for Scientific Innovation

Addressing Unmet Needs Through Technology

Anticipating the Path Ahead

Leave a Comment

Healthcare Innovation: ������ֳ� and KU Leuven’s Collaborative Approach

Leave a Comment

Embracing patient-centered research: the transformative power of partnership

Understanding the patient perspective

The power of partnership

Enhancing research through patient insights

Leave a Comment

������ֳ�'s Commitment to Innovation in Drug Development

Leave a Comment

��ֳ� and Ailux Biologics Join Forces to Transform Biologics Research

Healthcare Innovation: ��ֳ� and KU Leuven’s Collaborative Approach

��ֳ�'s Commitment to Innovation in Drug Development